Daily Roundup | Jaypirca Adds a First-Line CLL Choice & Novartis Signs $575M Abogen License

Delayed Friday edition, recorded October 2. Lilly's Jaypirca (pirtobrutinib) gains first-line approval for adults with CLL/SLL without a known 17p deletion—but how does a trial against older chemotherapy guide today's treatment choice? Novartis agrees to $575 million upfront for Abogen's early-stage RNA medicine ABO2203, with closing still pending and autoimmune benefit unproven. Also: Pfizer's Litfulo (ritlecitinib) advances toward vitiligo filings; Biogen reports longer-term litifilimab results in cutaneous lupus without a continuing placebo comparison; and Bayer plans a $2.2 billion Ohio manufacturing site.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.